Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
PBM
PBM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PBM News
Psyence BioMed Enters Put Option Agreement with PsyLabs
2d ago
Newsfilter
Psyence Biomedical Settles Shareholder Claim for $1.5 Million
5d ago
Newsfilter
PSYENCE BIOMEDICAL LTD TO PAY KAOS CAPITAL $1.5 MILLION IN SETTLEMENT
5d ago
moomoo
Teradyne Q4 Earnings Beat Estimates, Shares Surge
Feb 03 2026
Benzinga
Psyence Biomedical Delays Reverse Stock Split Implementation
Feb 02 2026
stocktwits
Psyence BioMed Announces Share Consolidation Plan
Jan 28 2026
Newsfilter
Psyence Biomedical (PBM) Announces 1-for-6.25 Reverse Stock Split Effective January 20, 2026
Jan 15 2026
seekingalpha
Psyence BioMed Executes 1-for-6.25 Share Consolidation, Reducing Outstanding Shares to 1.02 Million
Jan 15 2026
Globenewswire
Psyence Biomedical Approves 2026 Financial Strategy and Share Repurchase Program
Jan 12 2026
Newsfilter
Psyence BioMed Becomes First Nasdaq Company to Produce GMP-Compliant Ibogaine HCl
Jan 05 2026
Globenewswire
Psyence BioMed Achieves First GMP-Compliant High-Purity Ibogaine Production on Nasdaq
Jan 05 2026
Newsfilter
Kraig Biocraft Laboratories Transitions to Spider Silk Commercialization with 22% Yield Increase
Dec 19 2025
Newsfilter
Psyence Biomedical Receives Approval for NPX5 in Phase IIb Clinical Trial
Dec 19 2025
Globenewswire
Psyence BioMed Receives Approval for Psilocybin Use in Phase IIb Clinical Trial
Dec 19 2025
Newsfilter
Psyence BioMed Achieves Clinical Milestones in 2025, Ends Year with Over $9 Million Cash Reserves
Dec 09 2025
Globenewswire
Psyence BioMed Highlights 2025 Achievements and 2026 Strategic Vision
Dec 09 2025
Newsfilter
Show More News
